INSM
INSMED Inc
NASDAQ · Healthcare · Biotechnology · US
$95.29
−1.02%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$96.27
From 52W high−54.93%
Volume2.72M
Market cap$20.81B
P/E (TTM)—
P/S (TTM)18.3x
Div yield—
Key dataOct 19, 2026
Open
$96.27
From 52W high
−54.93%
Volume
2.72M
Market cap
$20.81B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−26.2x
P/E (TTM)
—
RSI (14)
28.9
MomentumView details →
1D Return
−1.02%
YTD Return
−44.77%
SummaryUpdated Jun 1, 2026
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company founded in 1988 and headquartered in Bridgewater, New Jersey. The company has evolved from its early days to become a specialized developer and commercializer of therapies for patients with serious and rare diseases, particularly focusing on respiratory conditions. Insmed went public in 2000 and has built its business around innovative drug delivery technologies and treatments for orphan diseases with significant unmet medical needs.
Similar companies
Latest newsMore news →
Insmed launched BRINSUPRI tablets 25 mg, an oral treatment for non-cystic fibrosis bronchiectasis, for prescription availability in Japan.10h agoInsmed announced that new respiratory-portfolio data will be presented at CHEST 2026 and INSMED Inc 2026.5d agoINSMED Inc shares slid following the CFO's exit.13d ago